Please ensure Javascript is enabled for purposes of website accessibility
Skip to main content
Poised to address unmet need in neuromuscular diseases and
positioned for growth

Press Releases

Press Releases

2026 2025 2024 2023 2022 2021 2020 2019 all

June 17, 2026

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

June 3, 2026

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

May 26, 2026

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

May 20, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2026

Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval

May 13, 2026

Dyne Therapeutics to Participate in Upcoming Investor Conferences

May 11, 2026

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

April 27, 2026

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

April 23, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2026

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

March 8, 2026

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)

March 8, 2026

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

March 2, 2026

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

February 25, 2026

Dyne Therapeutics to Participate in Upcoming Investor Conferences

February 22, 2026

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

January 20, 2026

Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1

January 7, 2026

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

December 23, 2025

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

December 11, 2025

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

December 9, 2025

Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
Displaying 1 - 20 of 163
Stay in touch

You are now leaving 
the Dyne Therapeutics corporate website

Continue